Text Size
   
YouCMSAndBlog Module Generator Wizard Plugin

PLPL

PLPL Is Today's Low Float Biotech Momentum Play!!!

Company:          Plandai Biotechnology, Inc.

Symbol:            PLPL.ob

Current PPS:      $0.43<===Ideal Entry Point

Outstanding Shares: 11.4M

Float:  8.4M <=== Low Float Big Gain Potential

10 Day Average Volume: 120K

Website: www.plandaibiotech.com

About the Company:

Plandai Biotechnology, Inc (PLPL) Is a Seattle, Washington based company who through their recent acquisition of Global Energy Solutions, Ltd. and its subsidiaries focus on transforming the world of nutraceuticals. PLPL's principle holdings consist of land, farms and infrastructure in South Africa.

PLPL extracts live plant material that provides the highest levels of bioavailabilty available on the market today.

PLPL will sell its extracts to the leading finished product manufacturers in the following sectors:
• Food & Beverage
• Cosmeceutical
• Wellness
Nutraceutical
• Anti-Aging
• Pharmaceutical

Currently, green tea extracts, with an average selling price of $500/kg, have poor bioavailability of between 1-10%.

Published USDA studies have proven that PLPL's proprietary plant extracts have improved bioavailability of between 60-80%, far exceeding anything currently available today. That's an impressive 6-8 times more than today's levels!!!

Why is this important?

PLPL's extracts include but are not limited to, gallate catechins from green tea, (catechin gallate (CG),epigallocatechin gallate (EGCG), gallocatechin gallate (GCG), and epicatechin gallate (ECG); carotenoids (lycopene)from tomatoes, as well as citrus bioflavonoids and limonoids.

For those of you who are unfamiliar with those terms let us explain their benefits.

PLPL's extracts are highly beneficial to consumers in terms of wellness.

For example, PLPL's gallate catechin extract will be the active ingredient in formulated products supporting weight loss, anti-aging, the lowering of blood cholesterol, the regulation of high blood pressure and controlling diabetes 1 and 2.

PLPL also plans to conduct scientific studies using its Green Tea Gallate Catechin Extract to authenticate previously published findings that green tea gallate catechins are a potential anti-MALARIA drug target.

PLPL's extracts provide consumers up to 80% more bioavailabilty then what is currently on the market while at the same time keeping their prices competitive with their counterparts.

The above reasons leave us to believe that PLPL is the most undervalued company in the budding nutraceutical market set to surpass $243 Billion in the U.S. By 2015, According to a New Report by Global Industry Analysts, Inc.

http://www.prweb.com/releases/nutraceuticals/dietary_supplements/prweb4563164.htm

With a projected income of around  $27M for 2012-2013 the current PPS of $.43 could be a steal for a company that could be trading over $1 very soon!!!

PLPL's low float of 8.4M makes this stock very attractive to traders as it has the ability to breakout big in a short amount of time with a sudden increase in volume.

The buzz around PLPL may reach an all time high tomorrow which could set off a burst in volume early.

Just last week PLPL released breaking news regarding the receipt of $13 million in financing.

Tomorrow's setting up to be a monumental day of trading for PLPL so we are urging all members to put PLPL on their radar and to be ready to pick up shares early tomorrow at 9:30am EST

As always remember to follow PennyStockLocks on Facebook and Twitter for the latest news and updates on PLPL and check your inbox early tomorrow for PSL's full in depth profile on PLPL.

Plandai Biotechnology, Inc. Announces $13 Million in New Financing
8:30a ET January 25, 2012 (Market Wire)

Plandai Biotechnology, Inc. (OTCBB: PLPL) Chief Executive Officer, Roger Duffield, today announced that the company, through its South African subsidiary, Dunn Roman Holdings Africa (Proprietary) Ltd, secured loan financing from the Land and Development Bank of South Africa in the amount of $13,000,000 (Rands 100 million). The Company has been notified by the Land Bank that they should anticipate receipt of the first tranche of funding on or about February 25, 2012.

Mr. Duffield stated, "The loan is non-dilutive in nature and there is no equity conversion feature. It is strictly a debt financing. These funds are designated for the Senteeko tea estate in Mpumalanga, South Africa, which grows green tea and produces a bioavailable botanical extract that will be exclusively sold by Plandai as an ingredient for the beverage and wellness industries."

Dunn Roman Holdings Africa (Proprietary) Ltd is currently valued at over $50 million (R400 million), with projected net profit of $19 million (R150 million) by 2017. The company has more than 3500 hectares of land consisting of tea estates, timber plantations and existing infrastructure valued at more than $8 million (R63 million) and secured by long term notarial leases through local communities who own these farms through South Africa Land Claim policies.

Mr. Duffield added, "The project is the first botanical extraction business in South Africa addressing the issues of unprofitable tea estates and making them more viable through the harvesting of fresh green tea leaf for the sole purpose of extracting a bioavailable green tea gallate catechin extract. Green tea extracts from the plant Camellia sinensis contain polyphenols and catechins, which are functional chemical compounds possessing nutritive properties that act effectively as preventive agents in the healthcare field. Polyphenols from green tea are an excellent source antioxidant and anti-carcinogenic substances.

The Northern American and European natural extracts market are emerging and in a state of intense competition. The shift towards natural ingredients is driving the expansion of the natural extracts market. Among the flurry of ingredients competing in the natural extracts market, green tea extracts is a pioneer and one of the most prominent success stories. (Frost & Sullivan Research, 2011)

"The dynamic growth of this industry using formulated green tea extracts as alternative medicine or as a synergistic combination therapy with pre-existing antiviral or antibiotics depends on a method of delivery that ensures its stability and greater bioavailability. Green tea and green tea extracts are one of the most researched agents in the natural botanical sector, with over 20 years of investigations supporting five hundred research studies published identifying markets and final products that deliver benefits in weight loss, anti-aging, treating diabetes 1 & 2, blood cholesterol lowering, treating high blood pressure, and relieving symptoms of certain cancers and malaria. The market for green tea is in a high growth stage with increasing annual volume growth rates between 13-14 percent. (Frost & Sullivan Research, 2011).

About Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc., through its recent acquisition of Global Energy Solutions, Ltd. and its subsidiaries, focuses on the farming of whole fruits, vegetables and live plant material and the production of proprietary functional foods and botanical extracts for the health and wellness industry. Its principle holdings consist of land, farms and infrastructure in South Africa.

Enhanced by Zemanta

FREE Stock Alerts

 

Partner Sites

Follow Us On

As Seen On...

IHUB

MarketWatch

Yahoo Finance

Google Finance

MSN

Penny Stock Picks